Pursuant to Regulation 30 read with Schedule III to the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (‘Listing Regulations’), Sai Life Sciences has informed that the Board of Directors of the Company has approved and allotted 41,510 fully paid-up equity shares of Re.1/ each upon exercise of options granted under ESOP 2018 and 5,000 fully paid-up equity shares of Re.1/ each upon exercise of options granted under ESOP 2008, vide circular resolution dated 23th April, 2025. The details required under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed as Annexure-A (ESOP 2018) and Annexure-C (ESOP 2008). Further, the details required as per SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024 are enclosed as Annexure-B (ESOP2018) and Annexure-D (ESOP 2008).
The above information is a part of company’s filings submitted to BSE.
